<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1169</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14694197</PubmedId>
            <Abstract>To generate broadly protective T cell responses more similar to those acquired after vaccination with radiation-attenuated Plasmodium falciparum sporozoites, we have constructed candidate subunit malaria vaccines expressing six preerythrocytic antigens linked together to produce a 3240-aa-long polyprotein (L3SEPTL). This polyprotein was expressed by a plasmid DNA vaccine vector (DNA) and by two attenuated poxvirus vectors, modified vaccinia virus Ankara (MVA) and fowlpox virus of the FP9 strain. MVAL3SEPTL boosted anti-thrombospondin-related adhesive protein (anti-TRAP) and anti-liver stage antigen 1 (anti-LSA1) CD8(+) T cell responses when primed by single antigen TRAP- or LSA1-expressing DNAs, respectively, but not by DNA-L3SEPTL. However, prime boost regimes involving two heterologous viral vectors expressing L3SEPTL induced a strong cellular response directed against an LSA1 peptide located in the C-terminal region of the polyprotein. Peptide-specific T cells secreted IFN-gamma and were cytotoxic. IFN-gamma-secreting T cells specific for each of the six antigens were induced after vaccination with L3SEPTL, supporting the use of polyprotein inserts to induce multispecific T cells against P. falciparum. The use of polyprotein constructs in nonreplicating poxviruses should broaden the target antigen range of vaccine-induced immunity and increase the number of potential epitopes available for immunogenetically diverse human populations.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>290-5</ArticlePages>
            <ArticleTitle>A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Prieur</LastName>
                    <ForeName>Eric</ForeName>
                </Author>
                <Author>
                    <LastName>Gilbert</LastName>
                    <ForeName>Sarah C</ForeName>
                </Author>
                <Author>
                    <LastName>Schneider</LastName>
                    <ForeName>Joerg</ForeName>
                </Author>
                <Author>
                    <LastName>Moore</LastName>
                    <ForeName>Anne C</ForeName>
                </Author>
                <Author>
                    <LastName>Sheu</LastName>
                    <ForeName>Eric G</ForeName>
                </Author>
                <Author>
                    <LastName>Goonetilleke</LastName>
                    <ForeName>Nilu</ForeName>
                </Author>
                <Author>
                    <LastName>Robson</LastName>
                    <ForeName>Kathryn J H</ForeName>
                </Author>
                <Author>
                    <LastName>Hill</LastName>
                    <ForeName>Adrian V S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Weatherall Institute of Molecular Medicine and Cellular Immunology, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom. eric.prieur@well.ox.ac.uk.</Affiliations>
            <ArticleChemicalList>Antigens, Protozoan;Malaria Vaccines;Protozoan Proteins;Vaccines, DNA;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Protozoan(genetics); CD8-Positive T-Lymphocytes(immunology); Cytotoxicity, Immunologic; Female; Fowlpox virus(genetics); Genetic Vectors; Interferon-gamma(biosynthesis); Malaria Vaccines(genetics; immunology); Malaria, Falciparum(immunology; prevention &amp; control); Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Plasmodium falciparum(genetics; immunology); Protozoan Proteins(genetics; immunology); Vaccines, DNA(genetics; immunology); Vaccinia virus(genetics)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>101</Volume>
                <Issue>1</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>LSA1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YYIPHQSSL</LinearSequence>
                        <StartingPosition>1671</StartingPosition>
                        <EndingPosition>1679</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q25893</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5833</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1</LocationOfData>
                <EpitopeId>76522</EpitopeId>
                <ReferenceStartingPosition>1671</ReferenceStartingPosition>
                <ReferenceEndingPosition>1679</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>16352</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YYIPHQSSL</LinearSequence>
                                            <StartingPosition>1671</StartingPosition>
                                            <EndingPosition>1679</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q25893</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>L3SEPTL</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 25 micrograms DNA, 2 weeks later boost injection with MVA encoding source protein or P.falciparum multi-antigen polyprotein L3SEPTL or source protein LSA1.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen is a construct including 6 P.falciparum antigens in a polyprotein of 3240aa. 5-10 days after boosting, PBMCs were collected and assayed. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>LSA1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YYIPHQSSL</LinearSequence>
                                        <StartingPosition>1671</StartingPosition>
                                        <EndingPosition>1679</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25893</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Mice primed with plasmid DNA encoding protein artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL) and boosted with modified vaccinia virus Ankara (MVA) encoding the same protein do not have higher levels of peptide specific CD8+ cells thananimal immuzixed with empty vectors. Similar results are seen when the boost injection is performed with MVA encoding source protein LSA1. In contrast, high responses are seen if the priming is performed with a DNA vaccine encoding the source protein LSA1. The levels of peptide specific CD8+ cells obtained with  the different immunization protocols correlates with the number of peptide specific IFN-g producing cells in the spleen.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>16363</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YYIPHQSSL</LinearSequence>
                                            <StartingPosition>1671</StartingPosition>
                                            <EndingPosition>1679</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q25893</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>L3SEPTL</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1 dose of recombiant MVA or fowlpox virus, 2 weeks later boost injection with the other virus.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen is a construct including 6 P.falciparum antigens in a polyprotein of 3240aa. 7 days after boosting, PBMCs were collected and assayed. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>LSA1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YYIPHQSSL</LinearSequence>
                                        <StartingPosition>1671</StartingPosition>
                                        <EndingPosition>1679</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25893</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice primed with  modified vaccinia virus Ankara (MVA) encoding  an artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL) and boosted with fowlpox virus encoding the same protein have a significant increase in peptide specific CD8+ cells. Similar results are seen when the prime and boost viruses are reversed. Positive results are thus seen in heterologous poxvirus immunizations, but no response is seen with immunization using the same virus for both priming and boosting. The same results are seen when spleen CD8+ cells are analyzed. The levels of peptide specific CD8+ cells with the different immunization protocols correlates with the number of peptide specific IFN-g producing cells in the spleen. The responses are comparable to those obtained when the viruses encode only the source protein LSA1, implying that the polyprotein is able to elicit a similar responses to the individual antigen when included in a heterologous virus prime-boost regime.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>16290</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q25893</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 25 micrograms DNA, 2 weeks later boost injection with MVA encoding source protein or P.falciparum multi-antigen polyprotein L3SEPTL or source protein LSA1.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>5-10 days after boosting, PBMCs were collected and assayed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>LSA1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YYIPHQSSL</LinearSequence>
                                        <StartingPosition>1671</StartingPosition>
                                        <EndingPosition>1679</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25893</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice primed with plasmid DNA encoding protein LSA1 and boosted with modified vaccinia virus Ankara (MVA) encoding the same protein have a significant increase in peptide specific CD8+ cells. Similar results are seen when the boost injection is performed with MVA encoding an artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL). In contrast, no response is seen if the priming is performed with a DNA vaccine encoding that polyprotein. The levels of peptide specific CD8+ cells with the different immunization protocols correlates with the number of peptide specific IFN-g producing cells in the spleen.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>16368</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YYIPHQSSL</LinearSequence>
                                            <StartingPosition>1671</StartingPosition>
                                            <EndingPosition>1679</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q25893</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>L3SEPTL</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1 dose of recombiant MVA or fowlpox virus, 2 weeks later boost injection with the same virus.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen is a construct including 6 P.falciparum antigens in a polyprotein of 3240aa. 7 days after boosting, PBMCs were collected and assayed. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>LSA1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YYIPHQSSL</LinearSequence>
                                        <StartingPosition>1671</StartingPosition>
                                        <EndingPosition>1679</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q25893</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Mice primed and boosted with modified vaccinia virus Ankara (MVA) or fowlpox viruses encoding an artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL) do not show higher levels of peptide specific CD8+ cells in blood or in spleen than empty vector immunized mice. In contrast, positive results are seen in heterologous poxvirus immunizations, where one virus is used for priming and the other for boosting. The levels of peptide specific CD8+ cells obtained with  the different immunization protocols correlates with the number of peptide specific IFN-g producing cells in the spleen.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>TRAP</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>INVAFNRFL</LinearSequence>
                        <StartingPosition>194</StartingPosition>
                        <EndingPosition>202</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P16893.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5833</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1</LocationOfData>
                <EpitopeId>27759</EpitopeId>
                <ReferenceStartingPosition>194</ReferenceStartingPosition>
                <ReferenceEndingPosition>202</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Thrombospondin-related anonymous protein precursor.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>16382</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P16893.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <Plasmid>
                                        <SubType>Plasmid</SubType>
                                    </Plasmid>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 25 micrograms DNA, 2 weeks later boost injection with MVA encoding source protein or P.falciparum multi-antigen polyprotein L3SEPTL or source protein TRAP.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>5-10 days after boosting, PBMCs were collected and assayed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>TRAP</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>INVAFNRFL</LinearSequence>
                                        <StartingPosition>194</StartingPosition>
                                        <EndingPosition>202</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P16893.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice primed with plasmid DNA encoding protein TRAP and boosted with modified vaccinia virus Ankara (MVA) encoding the same protein have a significant increase in peptide specific CD8+ cells. Similar results are seen when the boost injection is performed with MVA encoding an artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL). In contrast, no responses are seen if the priming is performed with a DNA vaccine encoding that polyprotein.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>16383</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>4-6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>INVAFNRFL</LinearSequence>
                                            <StartingPosition>194</StartingPosition>
                                            <EndingPosition>202</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P16893.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>L3SEPTL</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 dose of 25 micrograms DNA, 2 weeks later boost injection with MVA encoding source protein or P.falciparum multi-antigen polyprotein L3SEPTL or source protein TRAP.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen is a construct including 6 P.falciparum antigens in a polyprotein of 3240aa. 5-10 days after boosting, PBMCs were collected and assayed. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>TRAP</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>INVAFNRFL</LinearSequence>
                                        <StartingPosition>194</StartingPosition>
                                        <EndingPosition>202</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P16893.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Mice primed with plasmid DNA encoding protein artificial polyprotein that includes 6 P.falciparum antigens (L3SEPTL) and boosted with modified vaccinia virus Ankara (MVA) encoding the same protein do not have higher levels of peptide specific CD8+ cells than animals immunized with empty vectors. Similar results are seen when the boost injection is performed with MVA encoding source protein TRAP. In contrast, high responses are seen if the priming is performed with a DNA vaccine encoding the source protein TRAP.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

